Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings data on Monday. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.26, FiscalAI reports. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. The firm had revenue of $35.10 million during the quarter, compared to the consensus estimate of $25.99 million.

Here are the key takeaways from Delcath Systems’ conference call:

• Record results and higher outlook: Third-quarter revenue rose 71% year over year to $35.1 million, with net income of $7 million and adjusted EBITDA of $11.5 million. Delcath raised 2026 revenue guidance to $115 million–$117 million and expects positive adjusted EBITDA for the year.
• Commercial adoption is expanding: HEPZATO treatment volume increased 72% year over year, with about 0.6 new patient starts per site per month and 33 active U.S. centers. The company expects at least 36 centers by year-end and cited growing use alongside systemic therapies as a demand driver.
• Pipeline progress is mixed: Delcath expects an interim analysis of its colorectal trial around the middle of 2027 and plans an early-2027 IND submission for cholangiocarcinoma, while breast-cancer trial enrollment remains slower than anticipated and its interim-analysis timing is unclear.
• Investment and seasonality remain considerations: R&D spending rose with increased trial activity, while commercial investment continued; management said quarterly profitability may vary. Fourth-quarter guidance assumes fewer treatment days around the holidays and a seasonal slowdown in new patient starts.

Delcath Systems Trading Up 35.8%

Shares of DCTH opened at $20.27 on Tuesday. The stock’s 50-day moving average price is $15.53 and its two-hundred day moving average price is $12.49. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $20.30. The company has a market capitalization of $703.37 million, a PE ratio of 2,029.03 and a beta of 0.62.

Analyst Upgrades and Downgrades

DCTH has been the subject of a number of research reports. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings downgraded shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. HC Wainwright lifted their price target on shares of Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday. BTIG Research increased their price objective on Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Finally, Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Q3 earnings were $0.17 per share, versus analysts’ expected loss of $0.09, and revenue of $35.1 million exceeded the $26.0 million consensus estimate. Zacks earnings report
• Positive Sentiment: Delcath guided to $115 million–$117 million in 2026 revenue, above the $106.2 million analyst consensus, and said it is targeting at least 36 active centers by year-end. The higher outlook and expansion target point to stronger expected commercial performance. 2026 guidance and active-center target
• Positive Sentiment: BTIG Research raised its price target to $25 from $21 and reiterated a Buy rating, reflecting a more bullish analyst view. BTIG Research rating information

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.